HealthQuill respiratory syncytial virus
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season compared to 94.1% in the first and 64.2% in the second.
Drugs Health Pharma

GSK’s vaccine for severe RSV shows 43.3% effectiveness in third year

GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.

Read More
Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,” after a single jab, according to a company statement. 
Drugs Health Pharma

‘Strong neutralizing responses’ shown in RSV vaccine trials: Pfizer says

Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,”.

Read More
The FDA has granted accelerated approval for an intravenous drug to treat Alzheimer's Disease, according to a statement.
Drugs Health Medical Pharma

GSK gets FDA nod for adult respiratory syncytial virus (RSV) vaccine

GSK races ahead of rivals Pfizer and Moderna in getting FDA approval for RSV vaccine.

Read More
X